On December 19, 2024, Omeros announced that its pivotal Phase 3 clinical trial of the MASP2 antibody Narsoplimab (OMS721) in...

CD19 remains a hot target in immunotherapy, driving innovation across a range of diseases. This is evidenced by recent approvals...

Obesity is increasingly undermining human health. Obesity, a chronic metabolic disease, has significantly impacted the health and quality of life...

What if a single cellular pathway could unlock new therapies for muscle regeneration, cancer, obesity, immune system regulation, and more?...

Recent studies have shown that various drugs, including small molecules, opioids, and antibiotics, can activate MRGPRX2 (Mas-related G-protein coupled receptor...

In July 2023, Eli Lilly made a nearly $2 billion bet on Versanis' ActRII inhibitor, Bimagrumab, citing its ability to...

Since December 2023, there have been several positive updates about drugs targeting MSLN. On December 19th, RemeGen announced that the...

Colorectal cancer (CRC) is recognized as one of the most common and life-threatening malignancies, with an increasing proportion of advanced...

Neuroendocrine neoplasms/tumors (NENs or NETs) are rare tumors that originate from specialized cells called neuroendocrine cells. These cells have characteristics...

Immunotherapy is an essential option for current disease treatment. However, most patients fail to respond adequately to existing immunotherapies, such...

  On November 13, 2023, Legend Biotech officially announced that its wholly-owned subsidiary, Legend Biotech Ireland Limited, has entered into...

Every year, on August 18th, the world comes together to observe World Breast Cancer Research Day—a day dedicated to raising...